We are live on ! Find out more
ALNA

Allena Pharmaceuticals
ALNA

Delisted

ALNA was delisted on the 7th of September, 2022.

Back to rankings

29 hedge funds and large institutions have $28.1M invested in Allena Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 10 increasing their positions, 6 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more repeat investments, than reductions

Existing positions increased: 10 | Existing positions reduced: 6

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

1% less capital invested

Capital invested by funds: $28.3M → $28.1M (-$193K)

3% less funds holding

Funds holding: 30 → 29 (-1)

25% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 4

Holders
29
Holders Change
-1
Holders Change %
-3.33%
% of All Funds
0.5%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.02%
New
3
Increased
10
Reduced
6
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$980K
2
Morgan Stanley
Morgan Stanley
New York
+$494K
3
Renaissance Technologies
Renaissance Technologies
New York
+$260K
4
Millennium Management
Millennium Management
New York
+$97.7K
5
KAS
Kestra Advisory Services
Texas
+$88.4K

Top Sellers

Rank Fund Capital Flow
1
WVP
Worth Venture Partners
New Jersey
-$286K
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$192K
3
Two Sigma Investments
Two Sigma Investments
New York
-$56K
4
BCM
Bridgeway Capital Management
Texas
-$36.6K
5
HF
HRT Financial
New York
-$31K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$5.2M – – –
FM
2
Frazier Management
Washington
$4.33M – – –
Point72 Asset Management
3
Point72 Asset Management
Connecticut
$3.9M – – –
TGI
4
TRV GP II
Massachusetts
$3.63M – – –
Fidelity Investments
5
Fidelity Investments
Massachusetts
$2.98M – – –
Vanguard Group
6
Vanguard Group
Pennsylvania
$2.55M +$980K +809,035 +70%
Morgan Stanley
7
Morgan Stanley
New York
$1.36M +$494K +407,599 +64%
WVP
8
Worth Venture Partners
New Jersey
$967K -$286K -236,000 -24%
Renaissance Technologies
9
Renaissance Technologies
New York
$911K +$260K +214,671 +44%
BCM
10
Bridgeway Capital Management
Texas
$456K -$36.6K -30,200 -8%
Geode Capital Management
11
Geode Capital Management
Massachusetts
$371K +$35.5K +29,323 +11%
PHS
12
PFM Health Sciences
California
$370K – – –
BlackRock
13
BlackRock
New York
$325K +$72.4K +59,804 +32%
Millennium Management
14
Millennium Management
New York
$244K +$97.7K +80,625 +75%
KAS
15
Kestra Advisory Services
Texas
$95K +$88.4K +73,000 New
Northern Trust
16
Northern Trust
Illinois
$85K – – –
Citadel Advisors
17
Citadel Advisors
Florida
$62K +$57.7K +47,630 New
State Street
18
State Street
Massachusetts
$45K +$41.5K +34,258 New
Bank of New York Mellon
19
Bank of New York Mellon
New York
$44K -$6.25K -5,160 -13%
ECM
20
ExodusPoint Capital Management
New York
$43K -$7.63K -6,300 -16%
LPL Financial
21
LPL Financial
California
$33K – – –
Osaic Holdings
22
Osaic Holdings
Arizona
$30K – – –
GG
23
Golden Green
South Carolina
$27K -$9.69K -8,000 -28%
LFF
24
Level Four Financial
Texas
$26K – – –
Bank of America
25
Bank of America
North Carolina
$8K +$22 +18 +0.3%
1
2

ALNA Hedge Fund Activity: Q2 2021 in Review

29 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Allena Pharmaceuticals (ALNA) for Q2 2021, worth a combined $28.1M — down 0.68% from $28.3M a quarter earlier.

Sellers outnumbered buyers: 4 funds closed out of ALNA and 3 opened new positions — a net loss of 1 holder — while 6 trimmed existing stakes and 10 added.

The largest buyer was Vanguard Group, adding an estimated $980K. The largest seller was Worth Venture Partners, cutting an estimated $286K.

  • 29 institutional investors held Allena Pharmaceuticals (ALNA) as of Q2 2021, down from 30 in Q1 2021.
  • Funds reported $28.1M of Allena Pharmaceuticals stock for Q2 2021, down 0.68% quarter-over-quarter.
  • 3 funds opened new Allena Pharmaceuticals positions in Q2 2021 and 4 closed out, a net change of -1 holder.
  • The largest Allena Pharmaceuticals buyer in Q2 2021 was Vanguard Group, an estimated $980K added.
  • The largest Allena Pharmaceuticals seller in Q2 2021 was Worth Venture Partners, an estimated $286K sold.

Based on aggregated 13F filings for Q2 2021.